http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform
-
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
-
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
-
Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
-
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
-
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
-
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
-
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
-
Evotec SE (EVO) and Pfizer Collaborate to Advance Drug Discovery in France
-
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
-
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
-
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
-
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
-
Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts
-
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
Pfizer (PFE) Reports Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO
-
Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults
-
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day
-
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
-
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
-
Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities
-
Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
-
Pfizer (PFE) and Genmab (GMAB) Reports TIVDAK sBLA Accepted for Priority Review by FDA
-
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
-
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
-
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts
-
Pfizer Declares First-Quarter 2024 Dividend
-
Pfizer (PFE) Completes Acquisition of Seagen (SGEN)
-
Pfizer Completes Acquisition of Seagen
-
Pfizer (PFE) Receives Approvals to Complete the Acquisition of Seagen
-
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
-
Pfizer (PFE) Announces FDA and EMA Acceped Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B
-
FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B
-
Pfizer (PFE) Presents New Marstacimab Phase 3 Data Showing Significant Bleed Reduction in Hemophilia A and B
-
Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B
-
Pfizer (PFE) Announces European Commission Approves ELREXFIO for Relapsed and Refractory Multiple Myeloma
-
European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma
-
Arvinas (ARVN) and Pfizer (PFE) Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE)
-
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
-
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15
-
Pfizer (PFE) announced Phase 2B trial of danuglipron showed statistically significant reductions from baseline in body weight for all doses
-
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
-
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
-
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting
-
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
Pfizer (PFE) and BioNTech (BNTX) Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
-
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19

